Federal Court Decisions

Decision Information

Decision Content


Date: 20210106

Docket: T-1893-19

Citation: 2021 FC 6

Ottawa, Ontario, January 6, 2021

PRESENT:  The Honourable Mr. Justice Phelan

BETWEEN:

JANSSEN INC, JANSSEN ONCOLOGY, INC

AND BTG INTERNATIONAL LTD

Plaintiffs

and

PHARMASCIENCE INC

Defendant

JUDGMENT

THIS COURT ADJUDGES, ORDERS AND DECLARES that:

  1. Canadian Patent No. 2,661,422 is, and has always been, invalid, void and of no effect by reasons of obviousness/obvious to try as asserted by the Defendant and is to be removed from the Patent Register.

  2. Except for this declaration of invalidity, the making, constructing, using or selling of PMS-ABIRATERONE, orally administered film-coated tablets containing 500 mg abiraterone acetate by Pharmascience Inc in accordance with its Abbreviated New Drug Submission No. 232148 would infringe the Asserted Claims.

  3. This action is dismissed with costs to the Defendant, the whole of which is to be the subject of a further determination by the Court.

blank

“Michael L. Phelan”

blank

Judge

 

 You are being directed to the most recent version of the statute which may not be the version considered at the time of the judgment.